Premium
Focal adhesion protein expression in human diffuse large B‐cell lymphoma
Author(s) -
Bosch Rosa,
DieguezGonzalez Rebeca,
Moreno María José,
Gallardo Alberto,
Novelli Silvana,
Espinosa Iñigo,
Céspedes María Virtudes,
Pavón Miguel Ángel,
Briones Javier,
Grañena Albert,
Sierra Jorge,
Mangues Ramon,
Casanova Isolda
Publication year - 2014
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.12381
Subject(s) - focal adhesion , immunohistochemistry , diffuse large b cell lymphoma , immunostaining , pathology , lymphoma , germinal center , medicine , proportional hazards model , cancer research , biology , cell , antibody , immunology , b cell , genetics
Aims Focal adhesions have been associated with poor prognosis in multiple cancer types, but their prognostic value in diffuse large B‐cell lymphoma ( DLBCL ) has not been evaluated. The aim of this study was to investigate the expression patterns and the prognostic value of the focal adhesion proteins FAK , Pyk2, p130Cas and HEF 1 in DLBCL . Methods and results Focal adhesion protein expression was examined using immunohistochemistry in normal lymphoid tissues and in 60 DLBCL patient samples. Kaplan–Meier survival and Cox regression analysis were performed to evaluate the correlation of focal adhesion protein expression with patient prognosis. FAK , Pyk2, p130Cas and HEF 1 expression was mostly found in the germinal centres of normal human lymphoid tissues. When assessed in DLBCL samples, FAK , Pyk2, p130Cas and HEF 1 were highly expressed in 45%, 34%, 42% and 45% of the samples, respectively. Multivariate Cox analysis revealed that decreased FAK expression was a significant independent predictor of poorer disease outcome. Conclusions FAK expression is an independent prognostic factor in DLBCL . Our results suggest that the addition of FAK immunostaining to the current immunohistochemical algorithms may facilitate risk stratification of DLBCL patients.